Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 309601, 7 pages
http://dx.doi.org/10.1155/2015/309601
Review Article

Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors

1Oncology Division, Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, EPE, Avenida Professor Egas Moniz, 1649-035 Lisbon, Portugal
2Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisbon, Portugal

Received 21 November 2014; Accepted 11 May 2015

Academic Editor: Bernardo L. Rapoport

Copyright © 2015 Ana Lúcia Costa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Roila, J. Herrstedt, M. Aapro et al., “Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference,” Annals of Oncology, vol. 21, no. 5, pp. v232–v243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Jordan, C. Sippel, and H.-J. Schmoll, “Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations,” The Oncologist, vol. 12, no. 9, pp. 1143–1150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Olver, R. A. Clark-Snow, E. Ballatori, B. T. Espersen, E. Bria, and K. Jordan, “Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential,” Supportive Care in Cancer, vol. 19, no. 1, pp. S33–S36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Grunberg, D. Warr, R. J. Gralla et al., “Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art,” Supportive Care in Cancer, vol. 19, supplement 1, pp. S43–S47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. P. J. Hesketh, “Chemotherapy-induced nausea and vomiting—review article,” The New England Journal of Medicine, vol. 358, no. 23, pp. 2482–2494, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Ettinger, M. Berger, D. Armstron et al., NCCN Clinical Practice Guidelines in Oncology—Antiemesis, version 2.2014, 2014.
  7. P. Hesketh, “Prevention and treatment of chemotherapy-induced nausea and vomiting,” UpToDate, 2014. View at Google Scholar
  8. E. Basch, A. A. Prestrud, P. J. Hesketh et al., “Antiemetics: american Society of Clinical Oncology clinical practice guideline update,” Journal of Clinical Oncology, vol. 29, no. 31, pp. 4189–2117, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Ellard, BCCA Protocol Summary for Adjuvant Therapy for High-Risk Breast Cancer using Cyclophosphamide (oral), Methotrexate and Fluorouracil, 2014.
  10. P. Hoskins, BBCA Guidelines for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults, BC Cancer Agency, 2014.
  11. K. S. Buser, R. A. Joss, D. Piquet et al., “Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study,” Annals of Oncology, vol. 4, no. 6, pp. 475–479, 1993. View at Google Scholar · View at Scopus
  12. B. Thiessen, “BCCA protocol summary for concomitant (dual modality) and adjuvant temozolomide for newly diagnosed malignant gliomas with radiation,” BC Cancer Agency Protocol Summary CNAJTZRT, 2014, http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/CNAJTZRT_Protocol_1Sep2014.pdf. View at Google Scholar
  13. B. Thiessen, BCCA Protocol Summary for Therapy for Malignant Brain Tumours Using Temozolomide, 2014.
  14. A. Rozzi, C. Nardoni, M. Corona et al., “Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study,” Supportive Care in Cancer, vol. 19, no. 5, pp. 697–701, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Klassa, BCCA Protocol Summary for Palliative Therapy for Malignant Melanoma with Brain Metastases Using Temozolomide, 2014.
  16. M. Aapro and J. Finek, “Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results,” Cancer Treatment Reviews, vol. 38, no. 2, pp. 120–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Knowling, BCCA Protocol Summary for Adjuvant Treatment of C-Kit Positive High Risk Gastrointestinal Stromal Cell Tumours Using Imatinib, 2014.
  18. M. Knowling, “BCCA Protocol Summary for Treatment of Advanced C-Kit Positive and C-Kit Negative Gastrointestinal Stromal Cell Tumours (GISTs) Using Imatinib (GLEEVEC),” 2014.
  19. C. Lee, BCCA Protocol Summary for Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib, 2014.
  20. Pfizer Canada Inc, Crizotinib (XALKORI) Product Monograph, Pfizer Canada Inc., Québec, Canada, 2014.
  21. K. Chi, “BCCA Protocol Summary for Androgen-Independent Prostate Cancer Using Estramustine Phosphate (Interim Version),” November 2014.
  22. Pfizer Canada Inc, MCYT Product Monograph, Pfizer Canada Inc, Québec, Canada, 2008.
  23. N. Murray, BCCA Protocol Summary for Palliative Therapy of Extensive Stage Small Cell Lung Cancer (SCLC) with Oral Etoposide, 2014.
  24. Bristol-Myers Squibb Canada, Etoposide (VEPESIDE) Product Monograph, Bristol-Myers Squibb Canada, 2008.
  25. L. H. Einhorn and M. J. Brames, “Emetic potential of daily oral etoposide,” Supportive Care in Cancer, vol. 14, no. 12, pp. 1262–1265, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. Bristol-Myers Squibb Canada, Lomustine (CeeNU) Product Monograph, Bristol-Myers Squibb Canada, Saint-Laurent, Canada, 2010.
  27. B. Thiessen, BCCA Protocol Summary for Lomustine (CCNU) for Treatment of Recurrent Malignant Brain Tumours, 2014.
  28. K. Savage, “BCCA Protocol Summary for the Treatment of Metastatic or Locally Advanced Basal Cell Carcinoma Using Vismodegib,” November 2014.